There are some Migraine treatmentBut people who suffer from this know that in general they are not enough. Therefore, scientists usually ask about new options and in applications other than options that have already been used. This last group has a case UbrogepantThe drug that has been used in the United States since 2019 and currently, according to a new study of scientists from several US research centers, I may have new applications.
The use remains the treatment of migraines. What is changing is the time when it is accepted, and the symptoms that he stops. And this is the fact that these scientists conducted a clinical study in which it is demonstrated that if it is done when what is detectedS symptoms in front of the headacheNot only are these symptoms improve. The headache itself, when it arrives, does it in a much more tolerant way.
It seems obvious. The sooner you take precautions, the better. However, with this treatment of migraines, they observed more important results than with others. At one time, when he was checked, the conclusion of clinical trials was that it was working, but it was nothing from another world. Now we know that this was simply not used at the most necessary time.
What is ubrogepant?
Ubrogepant is the drug Antagonist of the peptide receptor associated with the calcitonin genomeThe field in Spain is not approved. However, there is another treatment for migraine of the same group of drugs that is more common. This is an athehepant, commercially known as Aquipta
Migraine treatment, which was not so much
In the first clinical trials that were carried out with UbroGepant in the United States, headaches were less intense compared to those who took placebo. Therefore, at the same time, the fact that he did not give remarkable side effects, his approval was decided as Migraine treatmentThe field, however, at all times it was known that this is not the best option.
It was necessary to improve the results of the drug, and for this many scientists wanted to study other methods of its introduction. Instead of using it when symptoms begin, can it be useful to take it earlier?
Symptoms that warn about what will happen
Angela diagnosed migraines for many years. The worst is headaches, of course. However, sometimes it also experiences previous symptoms that are not always identified in time, but this turns out to be a notification about what should happen.
“Sometimes there are symptoms of warning, and in other cases,” he explains. “In some cases, the first thing you notice is what you see badly, as if myopia grown shortly, and also flashes, for example, when you squeeze your eyes.” In addition, he refers to “nausea, before and during migraine, sensations of dizziness and discomfort in the face of touch.”
According to visual problems, they arise when it is Migraine with aura. But in general, each migraine can be accompanied by these previous symptoms. The most common, in addition to those that it mentions, are usually Fatigue, sensitivity to light, food craving and pain in the neck.
Clinical test for moving the well -known treatment of migraine
To conduct a study just just published, its authors 438 people with frequent migraines And warning signs a few hours ago. Everyone occupied two tablets, one, when the first signals began, while the others – only at the beginning of the second round of symptoms. In all cases, one of these tablets was a placebo, but they did not know which one.
After treatment, the seriousness of the migraine was evaluated using automatic examinations, in which after 5 points the ability to conduct a normal life was evaluated, despite the pain.
Thus, it was evident that when the first tablet was Ubrogepant, there was a clear difference in the treatment of migraine. Two hours after they had 73 % more often function normallyIn addition, the next day, 65 % of these people claimed that they feel very little or nothing limited. This percentage was 48 % for those who took placebo in the first round.
All this applies to the migraine itself. However, previous symptoms, known as ProtestThey also decreased. For example, 3 hours after taking the drug in the first shot, 27.3 % reported a lack of fatigue compared to 16.8 % that the placebo took. As for the pain in the neck, the interest was 28.9 % and 15 %, respectively. And there were also differences with dizziness, which was the third below 24 hours after the dose between those who first took the medicine.
On the other hand, when the placebo was at the beginning, and the drug was taken with already begun migraine, there were hardly any differences.
This means that the problem was not in the drug as such, but at present it was taken. Will these conclusions approve UBROGEPANT in more countries? Will they be the results applicable to drugs, such as our Atogepant? We will have to wait to find out the answers; But at least we already know that there may be a way to cut with migraine from the root. This is good news for those who suffer.
Source: Hiper Textual
